特发性肺纤维化的治疗进展

Advances in treatment of idiopathic pulmonary fibrosis

特发性肺纤维化是间质性肺病的一种特殊类型,病因不明,传统药物治疗效果不佳且毒副作用明显。尚无临床试验证实传统药物如抗炎药物、细胞毒性药物和免疫抑制剂有效,而免疫调节剂、抗纤维化药物、抗氧化剂、内皮素受体拮抗剂、肿瘤坏死因子阻滞剂、抗白三烯药物、甲磺酸伊马替尼等药物的有关临床试验已取得一定进展。总之,目前尚缺乏被高质量的临床试验证实有效的药物。肺移植可用于特发性肺纤维化的治疗,治疗效果肯定但供体有限。本文对近年来特发性肺纤维化治疗的进展作一综述。

Idiopathic pulmonary fibrosis（IPF）, whose cause remains unclear, is a specific kind of interstitial lung diseases. The effect of tranditional drugs treating for it does not work satisfactorily, in spite of its obvious side effect. For the past few years, traditional drugs such as corticosteroids, cytotoxie and immunosuppressive agents have not been confirmed as effective drugs by clinicial trials. New drugs such as immunomodulators, antifibrotic agents, antioxidants and so on have been introduced into clinical use and achieved certain progress. In short, there is a shortage of drugs that are prored effective by high-qualified clinic experiments. Lung transplantation can be used for treatment of IPF and has good effect but the donor is rare. The article reviewed the advances of treatment in IPF.